成人急性髓细胞白血病的诊断与治疗进展

金洁; 周一乐

doi:10.13201/j.issn.1004-2806.2022.05.002

成人急性髓细胞白血病的诊断与治疗进展

金洁^1, ,,
周一乐¹

- 浙江大学医学院附属第一医院血液科浙江大学癌症研究院浙江省血液病临床研究中心浙江省血液肿瘤(诊治)重点实验室(杭州，310003)
基金项目:
国家自然科学基金国际合作重点项目(No：81820108004)；国家自然科学基金(No：82170144-H0809)；浙江省科学技术厅重大项目(No：491010+J3210NZJ)

详细信息

作者简介:
金洁，医学博士，浙江大学二级教授、主任医师、博士生导师，享受国务院特殊津贴。全国三八红旗手、全国卫生系统先进工作者、浙江大学好医生。现任浙江大学医学院附属一院血液科名誉主任、学科带头人、浙江省血液肿瘤(诊治)重点实验室主任，国家卫健委临床重点学科-血液病学科带头人，浙江省血液病临床医学研究中心主任、浙江大学癌症研究院恶性血液病基础与临床研究团队负责人。中国女医师协会血液肿瘤专委会主任委员、CSCO抗白血病联盟副主任委员、CSCO抗淋巴瘤联盟常务委员、中国抗癌协会整合血液病副主任委员、中国医师协会血液病医师分会常务委员、海峡两岸血液病专委会常务委员、浙江省医师协会血液病分会会长、中国抗癌协会血液病转化专委会名誉主任委员。以第一完成人获得2011年国家科技进步二等奖1项、浙江省科学技术进步奖一等奖2项、二等奖4项。以第一与通讯作者(共同)在Lancet Oncol，Cell，JCO，Blood，Leukemia，JHO等国际期刊上发表SCI论文170余篇

通讯作者: 金洁，E-mail：jiej0503@zju.edu.cn；jiej0503@163.com

中图分类号: R733.71

收稿日期: 2022-04-19

刊出日期: 2022-05-01

Progress in diagnosis and treatment of acute myeloid leukemia in adult

JIN Jie^1, ,,
ZHOU YIle¹

More Information

Corresponding author: JIN Jie, E-mail: jiej0503@zju.edu.cn; jiej0503@163.com

Received Date: 19 April 2022

Publish Date: 01 May 2022

摘要

- 急性髓细胞白血病 /
- 诊断 /
- 治疗
- acute myeloid leukemia /
- diagnosis /
- treatment

HTML全文

参考文献(18)

[1]	Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges[J]. Blood Rev, 2019, 36: 70-87. doi: 10.1016/j.blre.2019.04.005
[2]	DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia[J]. N Engl J Med, 2020, 383(7): 617-629. doi: 10.1056/NEJMoa2012971
[3]	Maiti A, DiNardo CD, Qiao W, et al. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis[J]. Cancer, 2021, 127(22): 4213-4220. doi: 10.1002/cncr.33814
[4]	DiNardo CD, Lachowiez CA, Takahashi K, et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia[J]. J Clin Oncol, 2021, 39(25): 2768-2778. doi: 10.1200/JCO.20.03736
[5]	Kadia TM, Reville PK, Borthakur G, et al. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial[J]. Lancet Haematol, 2021, 8(8): e552-e561. doi: 10.1016/S2352-3026(21)00192-7
[6]	Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials[J]. Lancet Oncol, 2014, 15(9): 986-996. doi: 10.1016/S1470-2045(14)70281-5
[7]	Fournier E, Duployez N, Ducourneau B, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia[J]. Blood, 2020, 135(8): 542-546. doi: 10.1182/blood.2019003471
[8]	Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation[J]. N Engl J Med, 2017, 377(5): 454-464. doi: 10.1056/NEJMoa1614359
[9]	Roboz GJ, Strickland SA, Litzow MR, et al. Updated safety of midostaurin plus chemotherapy in newly diagnosed FLT3 mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program[J]. Leuk Lymphoma, 2020, 61(13): 3146-3153. doi: 10.1080/10428194.2020.1805109
[10]	Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD[J]. Blood, 2019, 133(8): 840-851. doi: 10.1182/blood-2018-08-869453
[11]	Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML[J]. N Engl J Med, 2019, 381(18): 1728-1740. doi: 10.1056/NEJMoa1902688
[12]	DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML[J]. N Engl J Med, 2018, 378(25): 2386-2398. doi: 10.1056/NEJMoa1716984
[13]	Pollyea DA, Tallman MS, de Botton S, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia[J]. Leukemia, 2019, 33(11): 2575-2584. doi: 10.1038/s41375-019-0472-2
[14]	Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J]. Blood, 2017, 130(6): 722-731. doi: 10.1182/blood-2017-04-779405
[15]	Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome[J]. Leukemia, 2019, 33(2): 379-389. doi: 10.1038/s41375-018-0312-9
[16]	Garcia-Manero G, Gore SD, Cogle C, et al. Phase Ⅰ study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia[J]. J Clin Oncol, 2011, 29(18): 2521-2527. doi: 10.1200/JCO.2010.34.4226
[17]	Wei AH, Döhner H, Pocock C, et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission[J]. N Engl J Med, 2020, 383(26): 2526-2537. doi: 10.1056/NEJMoa2004444
[18]	Lancet JE, Uy GL, Cortes JE, et al. CPX-351(cytarabine and daunorubicin)Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia[J]. J Clin Oncol, 2018, 36(26): 2684-2692. doi: 10.1200/JCO.2017.77.6112